422 related articles for article (PubMed ID: 27738796)
21. Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation.
Yeh SP; Lo WC; Hsieh CY; Bai LY; Lin CC; Lin PH; Lin CY; Liao YM; Chiu CF
Support Care Cancer; 2014 May; 22(5):1199-206. PubMed ID: 24317849
[TBL] [Abstract][Full Text] [Related]
22. Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study.
Mukhopadhyay S; Kwatra G; Alice K P; Badyal D
Support Care Cancer; 2017 Jan; 25(1):145-154. PubMed ID: 27591991
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC).
Karthaus M; Tibor C; Lorusso V; Singh-Arora R; Filippov A; Rizzi G; Borroni ME; Rossi G; Grunberg SM
Support Care Cancer; 2015 Oct; 23(10):2917-23. PubMed ID: 25724407
[TBL] [Abstract][Full Text] [Related]
24. NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.
Aapro M; Karthaus M; Schwartzberg L; Bondarenko I; Sarosiek T; Oprean C; Cardona-Huerta S; Hansen V; Rossi G; Rizzi G; Borroni ME; Rugo H
Support Care Cancer; 2017 Apr; 25(4):1127-1135. PubMed ID: 27885469
[TBL] [Abstract][Full Text] [Related]
25. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
26. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
Schwartzberg L; Barbour SY; Morrow GR; Ballinari G; Thorn MD; Cox D
Support Care Cancer; 2014 Feb; 22(2):469-77. PubMed ID: 24141698
[TBL] [Abstract][Full Text] [Related]
27. [Palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in Italy: pharmacologic, clinical and economic aspects].
Pradelli L; Eandi M
Tumori; 2008; 94(2):suppl 26-32. PubMed ID: 18564623
[No Abstract] [Full Text] [Related]
28. Evaluation of antiemetic effect of intravenous palonosetron versus intravenous ondansetron in laparoscopic cholecystectomy: a randomized controlled trial.
Laha B; Hazra A; Mallick S
Indian J Pharmacol; 2013; 45(1):24-9. PubMed ID: 23543732
[TBL] [Abstract][Full Text] [Related]
29. Palonosetron versus ondansetron as rescue medication for postoperative nausea and vomiting: a randomized, multicenter, open-label study.
Candiotti KA; Ahmed SR; Cox D; Gan TJ
BMC Pharmacol Toxicol; 2014 Aug; 15():45. PubMed ID: 25127659
[TBL] [Abstract][Full Text] [Related]
30. Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
Yeh YC; McDonnell A; Klinger E; Fowler B; Matta L; Voit D; Reddy P
J Oncol Pharm Pract; 2011 Sep; 17(3):179-85. PubMed ID: 20452991
[TBL] [Abstract][Full Text] [Related]
31. A prospective study of the antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimen.
Miyata Y; Yakushijin K; Inui Y; Imamura Y; Goto H; Mizutani Y; Kurata K; Kakiuchi S; Sanada Y; Minami Y; Kawamoto S; Yamamoto K; Ito M; Tominaga R; Gomyo H; Mizuno I; Nomura T; Kitagawa K; Sugimoto T; Murayama T; Matsuoka H; Minami H
Int J Hematol; 2016 Dec; 104(6):682-691. PubMed ID: 27612464
[TBL] [Abstract][Full Text] [Related]
32. Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT.
Musso M; Scalone R; Crescimanno A; Bonanno V; Polizzi V; Porretto F; Bianchini C; Perrone T
Bone Marrow Transplant; 2010 Jan; 45(1):123-7. PubMed ID: 19483762
[TBL] [Abstract][Full Text] [Related]
33. A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin.
Maeda A; Ura T; Asano C; Haegawa I; Nomura M; Komori A; Narita Y; Taniguchi H; Kadowaki S; Muro K; Horio Y; Yoshida T; Oze I; Kajita M; Mizutani A
Asia Pac J Clin Oncol; 2016 Sep; 12(3):254-8. PubMed ID: 27030364
[TBL] [Abstract][Full Text] [Related]
34. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.
Celio L; Frustaci S; Denaro A; Buonadonna A; Ardizzoia A; Piazza E; Fabi A; Capobianco AM; Isa L; Cavanna L; Bertolini A; Bichisao E; Bajetta E;
Support Care Cancer; 2011 Aug; 19(8):1217-25. PubMed ID: 20574663
[TBL] [Abstract][Full Text] [Related]
35. A randomized, double-blind trial of palonosetron compared with ondansetron in preventing postoperative nausea and vomiting after gynaecological laparoscopic surgery.
Park SK; Cho EJ
J Int Med Res; 2011; 39(2):399-407. PubMed ID: 21672343
[TBL] [Abstract][Full Text] [Related]
36. A prospective study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in malignant lymphoma patients following highly emetogenic chemotherapy.
Takahashi T; Okada T; Ikejiri F; Ito S; Okada Y; Takahashi F; Kumanomido S; Jo Y; Adachi K; Onishi C; Kawakami K; Miyake T; Inoue M; Suzuki R; Suzumiya J
Int J Clin Oncol; 2018 Feb; 23(1):189-194. PubMed ID: 28823027
[TBL] [Abstract][Full Text] [Related]
37. Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy.
Wang SY; Yang ZJ; Zhang L
Asian Pac J Cancer Prev; 2014; 15(22):9587-92. PubMed ID: 25520071
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
Oyama K; Fushida S; Kaji M; Takeda T; Yabushita K; Nezuka H; Kinami S; Kadoya N; Takai Y; Tsukioka Y; Ohyama S; Tsuji K; Tsukada T; Kinoshita J; Fujimura T; Ohta T
Int J Clin Oncol; 2016 Jun; 21(3):483-90. PubMed ID: 26507140
[TBL] [Abstract][Full Text] [Related]
39. Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study.
Trifilio S; Welles C; Seeger K; Mehta S; Fishman M; McGowan K; Strejcek K; Eiten E; Pirotte C; Lucier E; DeFrates S; Mehta J
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):584-589. PubMed ID: 28694084
[TBL] [Abstract][Full Text] [Related]
40. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
Fox-Geiman MP; Fisher SG; Kiley K; Fletcher-Gonzalez D; Porter N; Stiff P
Biol Blood Marrow Transplant; 2001; 7(11):596-603. PubMed ID: 11760147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
